Damora Therapeutics (DMRA) director files Form 3 initial ownership report

Rhea-AI Filing Summary

Damora Therapeutics, Inc. director Turtle Cameron filed an initial statement of beneficial ownership on Form 3. The filing reports no purchases, sales, grants, gifts, or other transactions, and shows no derivative positions or holdings disclosed in this dataset.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.,

221 CRESCENT ST, BUILDING 23, SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Garrett Winslow, attorney-in-fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Damora Therapeutics (DMRA) Form 3 filing by Turtle Cameron show?

The Form 3 shows that director Turtle Cameron filed an initial beneficial ownership report. It lists no buy, sell, gift, or derivative transactions and no remaining derivative positions in the summarized data.

Did Turtle Cameron buy or sell any Damora Therapeutics (DMRA) shares in this Form 3?

No buy or sell activity is reported. The transaction summary lists 0 buys, 0 sells, and 0 derivative transactions, indicating no trading activity is disclosed in this filing snapshot.

Are there any options or derivative securities reported for Damora Therapeutics (DMRA) in this Form 3?

No derivative positions are listed. The derivativeTransactionCount is zero and the derivative summary is empty, indicating no options, warrants, or similar instruments are shown in this data.

Does the Damora Therapeutics (DMRA) Form 3 indicate any gifts or tax-related share dispositions?

The filing data shows no such activity. giftCount and taxWithholdingCount are both zero, meaning no gifts or tax-withholding share dispositions are recorded in this Form 3 summary.

What is the net share change reported in this Damora Therapeutics (DMRA) Form 3?

The net change is zero. The summary lists netBuySellShares of 0 and a netBuySellDirection of “neutral,” reflecting no reported acquisitions or dispositions of DMRA shares in this filing.